Politics: Moderate House Democrats threaten drug pricing bill in House panel

3 Key Divides in Democrats’ Civil War Over the Biden Agenda

  3 Key Divides in Democrats’ Civil War Over the Biden Agenda It’s not just progressives versus moderates.Joe Biden may have less room for error.

a man wearing a suit and tie talking on a cell phone: Moderate House Democrats threaten drug pricing bill in House panel © Greg Nash Moderate House Democrats threaten drug pricing bill in House panel

Three moderate House Democrats announced that they would vote against their party's legislation to lower drug prices in committee on Tuesday, threatening a defeat for one of Democrats' signature measures.

Reps. Kurt Schrader (D-Ore.), Scott Peters (D-Calif.) and Kathleen Rice (D-N.Y.) announced in separate statements on Tuesday that they would vote against the section of Democrats' $3.5 trillion package dealing with lowering drug prices during a markup in the House Energy and Commerce Committee, which is currently ongoing.

Centrists throw wrench in House Democrats’ drug pricing plans

  Centrists throw wrench in House Democrats’ drug pricing plans The standoff is threatening the entire health plank of the party's mammoth social spending proposal.House Energy and Commerce Chair Frank Pallone (D-N.J.) and his senior aides are racing to shore up support for leadership-backed language that would allow direct government negotiations over the prices of hundreds of drugs, penalize manufacturers that raise prices faster than inflation and apply both policies to private insurance plans as well as Medicare.

The committee has not yet turned to the drug pricing section, but if all three lawmakers stick to their statements and vote no, it would be enough to defeat that section, given that all Republicans are also expected to vote no.

All three lawmakers last week put forward scaled-back, rival drug pricing legislation that they said would "preserve innovation" and could gain bipartisan support. The pharmaceutical industry has attacked the drug pricing bill backed by Democratic leaders, known as H.R. 3, as threatening innovation from drug companies.

"We need to be serious about how to address this issue by ensuring we champion legislation with broadly supported policies that have the bipartisan, bicameral backing needed to pass Congress," Schrader said in a statement. "I do not believe the drug pricing provision before the Energy and Commerce Committee today will meet this goal and succeed in the Senate, so I cannot vote in favor of the title."

Overnight Health Care — Nicki Minaj stokes uproar over vaccines

  Overnight Health Care — Nicki Minaj stokes uproar over vaccines Welcome to Tuesday's Overnight Health Care, where we're following the latest moves on policy and news affecting your health. Subscribe here: thehill.com/newsletter-signup.Rap star Nicki Minaj is under scrutiny from many critics for tweeting about her decision not to get the COVID-19 vaccine, and for promoting an unsubstantiated story to her millions of followers."She should be thinking twice about propagating information that really has no basis as except a one-off anecdote," White House chief medical adviser Anthony Fauci told CNN's Jake Tapper. "That's not what science is all about.

He said he would engage "in continued conversations with my colleagues" about the path forward.

A spokesperson for the House Energy and Commerce Committee did not provide specifics on the path forward.

"Democrats are committed to leveling the playing field and reining in the soaring cost of prescription drug prices for the American people," the spokesperson said. "The Energy and Commerce markup of the Build Back Better Act is ongoing and the Chairman continues to work to favorably report out all of the Committee's reconciliation legislative recommendations."

H.R. 3, would allow the Health and Human Services secretary to negotiate lower drug prices, a long-held Democratic goal. It would also cap drug prices based on prices paid in other wealthy countries.

While the moderates are flexing their muscles in the House, the drug pricing provisions were already expected to be changed before the final version of the $3.5 trillion package, given that Senate Democratic moderates also have concerns.

Senate Finance Committee Chairman Ron Wyden (D-Ore.) is working on his own drug pricing legislation, which is expected to be less far-reaching than H.R. 3, though the details are not yet finalized.

The troubles in the House, though, are a setback for moving the issue forward and illustrate the divisions within the party.

Why Are There So Many Democrats to Joe Biden’s Right? .
Political necessity doesn’t explain moderate opposition to the $3.5 trillion Build Back Better Act.During his 36 years in the Senate, Biden was a walking, talking weather vane. Wherever political winds blew, he followed. He was for school integration before his constituents were against it. He was skeptical of “tough on crime” politics before the electorate clamored for it. You might let your conscience be your guide; Biden stuck with the median voter.

See also